| Catalog No. | Size | Price (USD) |
| 40592-R0004-20 | 20 µg | $296.22 |
| 40592-R0004-100 | 100 µg | $592.44 |
General Information
| Product name | SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody, Rabbit Mab |
| Validated applications | ELISA (FAQ Protocol), IHC-P (FAQ Protocol), FCM (FAQ Protocol), ICC/IF (FAQ Protocol), Neutralization |
| Application notes | (Antibody's applications have not been validated with corresponding viruses. Optimal concentrations/dilutions should be determined by the end user.) |
| Specificity | SARS-CoV-2 Spike RBD Protein (Can block the binding between RBD and ACE2) Has cross-reactivity in ELISA with SARS-COV-2 Omicron (KP.2) Spike S1+S2 trimer Protein (Cat# 40589-V08H61) SARS-CoV-2 Omicron (XBB.1.16) Spike S1+S2 trimer Protein (Cat# 40589-V08H48) SARS-CoV-2 Omicron (XBB.1.5) Spike RBD Protein (Cat# 40592-V08H146) SARS-CoV-2 Omicron (XBB.1.5) Spike S1+S2 trimer Protein (Cat# 40589-V08H45) SARS-CoV-2 Omicron (XBB.1) Spike S1+S2 trimer Protein (Cat# 40589-V08H42) SARS-CoV-2 Omicron (XBB) Spike RBD Protein (Cat# 40592-V08H144) SARS-CoV-2 Omicron (BQ.1.1) Spike S1+S2 trimer Protein (Cat# 40589-V08H41) SARS-CoV-2 Omicron (BQ.1.1) Spike RBD Protein (Cat# 40592-V08H143) SARS-CoV-2 Omicron (BF.7) Spike S1+S2 trimer Protein (Cat# 40589-V08H39) SARS-CoV-2 Omicron (BA.4.6/BF.7) Spike RBD Protein (Cat# 40592-V08H140) SARS-CoV-2 Omicron (BA.4.6) Spike S1+S2 trimer Protein (Cat# 40589-V08H37) SARS-CoV-2 Omicron (BA.2.75) Spike RBD Protein (Cat# 40592-V08H135) SARS-CoV-2 Omicron (BA.2.75) Spike S1+S2 trimer Protein (Cat# 40589-V08H36) SARS-CoV-2 Omicron (BA.2.75.2) Spike RBD Protein (Cat# 40592-V08H141) SARS-CoV-2 Omicron (BA.2.75.2) Spike S1+S2 trimer Protein (Cat# 40589-V08H38) SARS-CoV-2 Omicron (BA.2.3.20) Spike RBD Protein (Cat# 40592-V08H142) SARS-CoV-2 Omicron (BA.1.1) Spike S1+S2 trimer Protein (Cat# 40589-V08H29) SARS-CoV-2 Omicron (BA.1.1) Spike RBD Protein (Cat# 40592-V08H129) SARS-CoV-2 Omicron (B.1.1.529) S1+S2 trimer Protein (Cat# 40589-V08H26) SARS-CoV-2 Omicron (B.1.1.529) Spike S1 Protein (Cat# 40591-V08H41) SARS-CoV-2 Omicron (B.1.1.529) Spike RBD Protein (Cat# 40592-V08H121) SARS-CoV-2 Omicron (BA.2) Spike S1+S2 trimer Protein (Cat# 40589-V08H28) SARS-CoV-2 Omicron (BA.2.12.1) Spike RBD Protein (Cat# 40592-V08H132) SARS-CoV-2 XD (BA.1 x AY.4) Spike S1+S2 trimer Protein (Cat# 40589-V08H30) SARS-CoV-2 Delta (B.1.617.2) Spike S1+S2 trimer Protein (Cat# 40589-V08H10) SARS-CoV-2 Delta (B.1.617.2) Spike S1+S2 Protein (Cat# 40589-V08B16) SARS-CoV-2 Delta (B.1.617.2) Spike S1 Protein (Cat# 40591-V08H23) SARS-CoV-2 Delta (B.1.617.2) Spike RBD Protein (Cat# 40592-V08H90) SARS-CoV-2 Spike RBD (K417T, E484K, N501Y) Protein (Cat# 40592-V08H86) SARS-CoV-2 Spike RBD (K417N, E484K, N501Y) Protein (Cat# 40592-V08H85) SARS-CoV-2 Spike RBD (N501Y) Protein (Cat# 40592-V08H82) SARS-CoV-2 Spike S1 Protein (Catalog#40591-V08B1) SARS-CoV-2 Spike RBD Protein (Catalog#40592-V08B) HCoV-HKU1 (isolate N1) Spike S1 Protein (Cat# 40021-V08H) Medium cross-reactivity in ELISA with SARS-CoV-2 Omicron (BA.2) Spike S1 Protein (Cat# 40591-V08H43) SARS-CoV-2 Omicron (BA.2) Spike RBD Protein (Cat# 40592-V08H123) Minimal cross-reactivity in ELISA with SARS-CoV-2 Omicron (BA.4) Spike RBD Protein (Cat# 40592-V08H130) No cross-reactivity in ELISA with SARS-CoV-2 Omicron (BA.2) Spike S1 NTD Protein (Cat# 40591-V08H44) SARS-CoV-2 Omicron (BA.5) Spike RBD Protein (Cat# 40592-V08H131) SARS-CoV-2 Delta (B.1.617.2) Spike S1 NTD Protein (Cat# 40591-V08H36) SARS-CoV Spike S1 Protein (Cat# 40150-V08B1) MERS-CoV Spike S1 Protein (Cat# 40069-V08B1) HCoV-HKU1 (isolate N5) Spike S1 Protein (Cat# 40602-V08H) HCoV-NL63 Spike S1 Protein (Cat# 40600-V08H) HCoV-229E Spike S1 Protein (Cat# 40601-V08H) HCoV-OC43 Spike S1+S2 ECD Protein (Cat# 40607-V08B) |
| Immunogen | Recombinant SARS-CoV-2 (2019-nCoV) Spike RBD-mFc Protein (Catalog#40592-V05H) |
| Preparation | This product is a recombinant monoclonal antibody expressed from HEK293 cells. |
| Source | Monoclonal Rabbit IgG Clone #0004 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Endotoxin | < 3 EU/mg |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Image / Experimental Information
| Image 1 Description | The neutralization activity is measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 Spike Pseudovirus (WT, Cat# PSV001), or SARS-CoV-2 Spike Omicron (B.1.1.529) Pseudovirus (Cat# PSV016), or SARS-CoV-2 Delta (B.1.617.2) variant Spike Pseudovirus (Cat# PSV011), under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40592-R0004). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. IC 50 (WT) is 0.12-2.95 µg/mL. IC 50 (Omicron) is 3.05-59.4 µg/mL. IC 50 (Delta) is 0.5-6.5 µg/mL. |
| Image 1 Alt Text | 2019-nCoV Coronavirus spike Microneutralizaiton (MN) 30748 |
| Image 1 URL | Source image |
| Image 2 Description | The neutralization activity is measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 Spike Pseudovirus (WT, Cat# PSV001), or SARS-CoV-2 Spike Omicron (B.1.1.529) Pseudovirus (Cat# PSV016), or SARS-CoV-2 Delta (B.1.617.2) variant Spike Pseudovirus (Cat# PSV011), under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40592-R0004). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. IC 50 (WT) is 0.12-2.95 µg/mL. IC 50 (Omicron) is 3.05-59.4 µg/mL. IC 50 (Delta) is 0.5-6.5 µg/mL. |
| Image 2 Alt Text | 2019-nCoV Coronavirus spike Enzyme linked immunosorbent assay (ELISA) 30753 |
| Image 2 URL | Source image |
| Image 3 Description | The neutralization activity is measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 Spike Pseudovirus (WT, Cat# PSV001), or SARS-CoV-2 Spike Omicron (B.1.1.529) Pseudovirus (Cat# PSV016), or SARS-CoV-2 Delta (B.1.617.2) variant Spike Pseudovirus (Cat# PSV011), under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40592-R0004). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. IC 50 (WT) is 0.12-2.95 µg/mL. IC 50 (Omicron) is 3.05-59.4 µg/mL. IC 50 (Delta) is 0.5-6.5 µg/mL. |
| Image 3 Alt Text | SARS-CoV-2 Coronavirus spike Flow Cytometry (FC) 32517 |
| Image 3 URL | Source image |
| Image 4 Description | The neutralization activity is measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 Spike Pseudovirus (WT, Cat# PSV001), or SARS-CoV-2 Spike Omicron (B.1.1.529) Pseudovirus (Cat# PSV016), or SARS-CoV-2 Delta (B.1.617.2) variant Spike Pseudovirus (Cat# PSV011), under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40592-R0004). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. IC 50 (WT) is 0.12-2.95 µg/mL. IC 50 (Omicron) is 3.05-59.4 µg/mL. IC 50 (Delta) is 0.5-6.5 µg/mL. |
| Image 4 Alt Text | SARS-CoV-2 Coronavirus spike Immunohistochemistry(IHC) 32672 |
| Image 4 URL | Source image |
| Image 5 Description | The neutralization activity is measured by microneutralization assay in vitro. The virus microneutralizaiton (MN) test was performed on 293T-ACE2 cells infected with SARS-CoV-2 Spike Pseudovirus (WT, Cat# PSV001), or SARS-CoV-2 Spike Omicron (B.1.1.529) Pseudovirus (Cat# PSV016), or SARS-CoV-2 Delta (B.1.617.2) variant Spike Pseudovirus (Cat# PSV011), under treatment of serial dilutions of neutralizing antibody. The infection was neutralized by increasing concentrations of Anti-SARS-CoV-2 Neutralizing Antibody (Catalog# 40592-R0004). Rate of inhibition was determined by comparing the Relative Light Unit (RLU) of Luciferase reporter in different antibody concentrations. IC 50 (WT) is 0.12-2.95 µg/mL. IC 50 (Omicron) is 3.05-59.4 µg/mL. IC 50 (Delta) is 0.5-6.5 µg/mL. |
| Image 5 Alt Text | SARS-CoV-2 Coronavirus spike Immunofluorescence(IF) 32694 |
| Image 5 URL | Source image |
Background Information
| Description | The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2 (angiotensin-converting enzyme 2), DPP4 (dipeptidyl peptidase-4), APN (aminopeptidase N), CEACAM (carcinoembryonic antigen-related cell adhesion molecule), Sia (sialic acid), O-ac Sia (O-acetylated sialic acid). The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate. |
| References |
|
title: Ribophorin-1 Governs Spike Abundance of Highly Pathogenic Coronaviruses by ER-associated degradation
authors: Huang Yi-Jiao; Lv Lu; ...; Qin Cheng-Feng
journal: bioRxiv
date: 2026-05-21
doi: 10.64898/2026.05.20.726704
cited_by_count: 0
techniques: Blocking Assay; Cell-Cell Fusion Assay; High Content Screening; Infection; Software; Staining; Variant Assay
bioz_score: 94
title: Machine learning approaches to dissect hybrid and vaccine-induced immunity
authors: Giorgio Montesi; Simone Costagli; ...; Annalisa Ciabattini
journal: Communications medicine
date: 2025-07-08
pmid: 40629157
doi: 10.1038/s43856-025-00987-4
cited_by_count: 4
techniques: Enzyme-linked Immunosorbent Assay
bioz_score: 94
title: Synthetic host defense peptide inhibits SARS-CoV-2 replication in vitro .
authors: Rhodri Harfoot; Blair Lawley; ...; Miguel E Quiñones-Mateu
journal: Antimicrobial Agents and Chemotherapy
date: 2025-06-23
pmid: 40548715
doi: 10.1128/aac.01700-24
cited_by_count: 0
techniques: Bicinchoninic Acid Protein Assay; Binding Assay; Cell Culture; Competitive ELISA; Concentration Assay; Control; Enzyme-linked Immunosorbent Assay; Generated; Incubation; Inhibition; Suspension; Virus
bioz_score: 94
title: Rapid Detection of Spike Protein Receptor Binding Region of SARS-CoV-2 and Its Variants Using a Nanosheet Probe.
authors: Jiacheng Yang; Jing Wang; ...; Liming Wang
journal: Analytical Chemistry
date: 2025-02-09
pmid: 39924735
doi: 10.1021/acs.analchem.4c06613
cited_by_count: 2
techniques: High Performance Liquid Chromatography; Labeling; Mass Spectrometry; Microscopy
bioz_score: 94
title: Virus-Mimetic Extracellular-Vesicle Vaccine Boosts Systemic and Mucosal Immunity via Immune Recruitment.
authors: Jingru Li; Haonan Xing; ...; Aiping Zheng
journal: ACS Nano
date: 2024-07-16
pmid: 39013102
doi: 10.1021/acsnano.4c01277
cited_by_count: 5
techniques: Expressing; Incubation; Microscopy; Staining
bioz_score: 94
title: Murine alveolar macrophages rapidly accumulate intranasally administered SARS-CoV-2 Spike protein leading to neutrophil recruitment and damage
authors: Chung Park; Il-Young Hwang; ...; Diane M Harper
journal: eLife
date: 2024-03-20
pmid: 38507462
doi: 10.7554/eLife.86764
pmcid: 10954308
cited_by_count: 3
techniques: Blocking Assay; Cell Culture; Expressing; FACS; Imaging; Luciferase; Plasmid Preparation; Recombinant; Staining; Transfection
bioz_score: 94
title: Naked-Eye Readable Microarray for Rapid Profiling of Antibodies against Multiple SARS-CoV-2 Variants
authors: Jingjie Nan; Yuan Chen; ...; Bai Yang
journal: Nano Letters
date: 2023-12-04
pmid: pm38047611
cited_by_count: 0
bioz_score: 93
title: Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2
authors: Ericka Kirkpatrick Roubidoux; Pamela H. Brigleb; ...; Randall T. Hayden
journal: Scientific Reports
date: 2023-10-19
pmid: 37857783
doi: 10.1038/s41598-023-44989-5
pmcid: 10587113
cited_by_count: 11
techniques: Concentration Assay; Enzyme-linked Immunosorbent Assay; Incubation; Infection; Luciferase; Luminex; Multiplex Assay; Neutralization; Protein Concentration; Software; Virus
bioz_score: 94
title: Cross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines
authors: Sabrina E. Vinzón; María V. Lopez; ...; Osvaldo L. Podhajcer
journal: NPJ vaccines
date: 2023-10-04
pmid: 37794010
pmcid: 10550992
cited_by_count: 2
techniques: Bioprocessing; Incubation
bioz_score: 94
title: Host heparan sulfate promotes ACE2 super-cluster assembly and enhances SARS-CoV-2-associated syncytium formation
authors: Qi Zhang; Weichun Tang; ...; Yihong Ye
journal: Nature Communications
date: 2023-09-18
pmid: 37723160
doi: 10.1038/s41467-023-41453-w
pmcid: 10507024
cited_by_count: 14
techniques: Purification; Recombinant
bioz_score: 93
title: Protein-DNA Conjugates with a Discrete Number of Oligonucleotide Strands for Highly Reproducible Protein Quantification by the DNA Proximity Assay.
authors: Yan Shan Ang; Lin-Yue Lanry Yung
journal: Analytical Chemistry
date: 2023-08-16
pmid: 37523447
doi: 10.1021/acs.analchem.3c02033
cited_by_count: 3
techniques: Recombinant
bioz_score: 93
title: Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein Expressed in Escherichia coli for the Development of Neutralizing Antibody Assay.
authors: Termsak Tantiwiwat; Apisitt Thaiprayoon; ...; Dujduan Waraho-Zhmayev
journal: Molecular biotechnology
date: 2023-03-02
pmid: 36103078
cited_by_count: 4
techniques: Binding Assay; Detection Assay
bioz_score: 94
title: Cyclophilin A-mediated mitigation of coronavirus SARS-CoV-2.
authors: Simranjeet Singh Sekhon; Woo-Ri Shin; ...; Yang-Hoon Kim
journal: Bioengineering & Translational Medicine
date: 2023-03-01
pmid: 36712291
cited_by_count: 10
bioz_score: 94
title: A Positron Emission Tomography Tracer Targeting the S2 Subunit of SARS-CoV-2 in Extrapulmonary Infections.
authors: Jianzhong Xian; Hongbin Huang; ...; Hongjun Jin
journal: Molecular Pharmaceutics
date: 2022-11-08
pmid: 36067000
doi: 10.1021/acs.molpharmaceut.2c00584
cited_by_count: 2
techniques: Immunohistochemistry; Incubation; Polymer; Staining
bioz_score: 94
title: Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2
authors: Mariana F. Tioni; Robert Jordan; ...; Roderick S. Tang
journal: NPJ vaccines
date: 2022-07-29
pmid: 35906244
doi: 10.1038/s41541-022-00509-6
pmcid: 9334537
cited_by_count: 32
bioz_score: 94
title: Magnetofluid-Integrated Multicolor Immunochip for Visual Analysis of Neutralizing Antibodies to SARS-CoV-2 Variants
authors: Haicong Shen; Xinying Chen; ...; Zhi Zhu
journal: Analytical Chemistry
date: 2022-06-03
pmid: 35658117
doi: 10.1021/acs.analchem.2c01260
pmcid: 9211038
cited_by_count: 9
bioz_score: 94
title: Characterization of the First SARS-CoV-2 Isolates from Aotearoa New Zealand as Part of a Rapid Response to the COVID-19 Pandemic.
authors: Rhodri Harfoot; Blair Lawley; ...; Miguel E Quiñones-Mateu
journal: Viruses
date: 2022-03-08
pmid: 35215963
doi: 10.3390/v14020366
cited_by_count: 8
techniques: Control; Derivative Assay; Immunofluorescence; Incubation; Infection; Virus
bioz_score: 94
title: Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates
authors: Wu Yi; Shen Yanqiong; ...; Wang Yucai
journal: bioRxiv
date: 2022-03-01
doi: 10.1101/2022.03.01.481391
cited_by_count: 0
techniques: Binding Assay; Enzyme-linked Immunosorbent Assay; Enzyme-linked Immunospot; Immunofluorescence; Incubation; Infection; Microscopy; Neutralization; Plaque Reduction Neutralization Test; Quantitative RT-PCR; Recombinant; Staining; Variant Assay
bioz_score: 94
title: Follicular T cells optimize the germinal center response to SARS-CoV-2 protein vaccination in mice
authors: Cecilia B. Cavazzoni; Benjamin L. Hanson; ...; Peter T. Sage
journal: Cell Reports
date: 2022-02-01
pmid: 35139367
doi: 10.1016/j.celrep.2022.110399
pmcid: 8806144
cited_by_count: 49
techniques: Activation Assay; Enzyme-linked Immunosorbent Assay; Recombinant; Software; Staining
bioz_score: 94
title: Rapid test to assess the escape of SARS-CoV-2 variants of concern
authors: Jacob T. Heggestad; Rhett J. Britton; ...; Ashutosh Chilkoti
journal: Science Advances
date: 2021-12-01
pmid: 34860546
doi: 10.1126/sciadv.abl7682
pmcid: 8641938
cited_by_count: 21
techniques: Derivative Assay
bioz_score: 93
